Xbrane Biopharma AB (STU:7XB) Total Equity : €34.83 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Total Equity?

Xbrane Biopharma AB's total equity for the quarter that ended in Mar. 2024 was €34.83 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Xbrane Biopharma AB Total Equity Historical Data

The historical data trend for Xbrane Biopharma AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Total Equity Chart

Xbrane Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

15.21

25.33

42.04

38.65

15.32

Xbrane Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Equity	Get a 7-Day Free Trial															32.76	34.28	28.00	15.32	34.83

Xbrane Biopharma AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Xbrane Biopharma AB's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	58.422	-	43.105
	=	15.32

Xbrane Biopharma AB's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2024 )	-	Total Liabilities(Q: Mar. 2024 )
	=	79.41	-	44.583
	=	34.83

Xbrane Biopharma AB Total Equity Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (STU:7XB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

XBRANE:Sweden 7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines